Biden aims to ensure access to COVID-19 therapeutics


New antiviral drugs for COVID-19 won't make a significant difference in efforts to reduce the pandemic's impact if patient access barriers cannot be overcome, experts say. The Biden administration is investing $650 million to expand production of rapid tests and promulgated a rule allowing pharmacists to prescribe, dispense and administer drugs for COVID-19, and other steps to reducing barriers could include allowing standing orders for the drugs and prescribing them as prevention for immunocompromised patients with suspected exposure.

Full story:

AABB SmartBrief

Transfusion and cellular therapies, including transplantation medicine

Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge.